This article was originally published on PharmaTimes http://www.pharmatimes.com/news/az_tagrisso_offers_sustained_benefit_in_lung_cancer_1231958

AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy.

Related Posts